Tag: beta-thalassemia
Tuesday, February 6th, 2024
Care Walk is the Cooley’s Anemia Foundation’s annual fundraising event and opportunity to bring together the thalassemia community and its supporters around the country. Funds raised support medical research to fight thalassemia, a genetic blood disorder, as well as patient support services for thalassemia patients across the country. Click here to register for Care Walk!! […]
Read more
: Blog, Care Walk, Events, Front Page, info foundation, info thalassemia, Links, Medical Research, News, person with thalassemia, Upcoming Events
: beta-thalassemia, Care Walk, care walk 2024, Care Walk Spotlight, CDC, Cooley's anemia, fundraiser, medical research, pharma, registration, Thal Pals, thalassemia, thalassemia awareness, thalassemia care, thalassemia care walk, thalassemia cure, thalassemia fundraiser, thalassemia medical research, what is thalassemia
Wednesday, January 17th, 2024
The FDA has approved Vertex and CRISPR’s gene-editing therapy Casgevy to treat beta thalassemia. Casgevy becomes the first therapy for the rare blood disorder to use the innovative CRISPR gene-editing technology. Vertex Pharmaceuticals and CRISPR Therapeutics have scored an FDA approval for their gene-editing therapy Casgevy (exa-cel) to treat transfusion-dependent beta thalassemia (TDT). The approval […]
Read more
: Blog, Front Page, info thalassemia, Links, Medical Research, News, person with thalassemia
: beta thalassemia cure, beta-thalassemia, casgevy, Cooley's anemia, CRISPR, gene editing, gene therapy, medical research, pharma, thalassemia, thalassemia cure, thalassemia treatment, vertex
Wednesday, January 3rd, 2024
Agios Announces Phase 3 ENERGIZE Study of Mitapivat Met Primary Endpoint and Both Key Secondary Endpoints in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia January 3, 2024 – Agios Pharmaceuticals, Inc. today announced that the global Phase 3 ENERGIZE study of mitapivat in adults with non-transfusion-dependent (NTD) alpha- or beta-thalassemia achieved its primary endpoint of […]
Read more
: Blog, Front Page, info thalassemia, medical professional, Medical Research, News, person with thalassemia, Webinars
: Agios, agospharmaceuticals, alpha thalassemia, beta-thalassemia, cooleys anemia foundation, energize, i have thalassemia, medical research for thalassemia, pharma, thalassemia, thalassemia care, thalassemia treatment, what is thalassemia
Tuesday, June 27th, 2023
The Cooley’s Anemia Foundation (CAF) recognizes the importance of maintaining health among thalassemia patients and is offering reimbursement of up to $500 for approved expenses related to health maintenance among U.S. thalassemia patients who are age 50 or older.
Read more
: Front Page, info thalassemia, News, Patients in the News, person with thalassemia
: beta-thalassemia, Cooley's anemia, cooleys anemia foundation, health maintenance, patient care, patients, reimbursement, thalassemia, thalassemia care, thalassemia major, thalassemia patients
Friday, October 7th, 2022
Are you or a loved one considering gene therapy as a treatment option for transfusion dependent beta thalassemia? Watch the recording of the Gene Therapy Webinar featuring Dr. Sujit Sheth and reps from bluebird bio now!
Read more
: Front Page, News, Webinars
: beta-thalassemia, bluebirdbio, gene therapy, pharma, Sujit Sheth, TDT, thalassemia, treatment, webinar, ZYNTEGLO
Thursday, September 22nd, 2022
Put these upcoming informational webinars on your calendar!
Read more
: Events, Front Page, Medical Research, Upcoming Events, Webinars
: beta-thalassemia, bluebird bio, caregiver education, gene therapy, patient education, Sujit Sheth, TDT, treatment, Weill Cornell, ZYNTEGLO
Wednesday, August 17th, 2022
bluebird bio, Inc. announced the FDA has approved ZYNTEGLO®, a one-time gene therapy custom-designed to treat the underlying genetic cause of beta‑thalassemia in adult and pediatric patients who require regular red blood cell transfusions.
Read more
: Blog, Front Page, Medical Research, News
: beta-thalassemia, bluebird bio, Clinical Trials in Thalassemia Cell and Gene Therapy, Cooley's anemia, fda, gene therapy, pharma, thalassemia, ZYNTEGLO
Wednesday, September 3rd, 2008
Researchers from Weill Cornell Medical College may have discovered the precise role of a gene in beta-thalassemia, The study, entitled “Decreased differentiation of erythroid cells exacerbates ineffective erythropoiesis in B-thalassemia” was published in the May 14, 2008 online issue of the journal Blood, the official publication of the American Society of Hematology (ASH). Splenectomy (spleen removal) […]
Read more
: News
: American Portuguese Biomedical Fund, Associazione per la Lotta alla Talassemia di Rovigo, AVLT, beta-thalassemia, CCBF, Children's Cancer and Blood Foundation, Dr. Stefano Rivella, National Institutes of Health, NIH, RoFAR, the Carlo and Micol Schejola Foundation, the Roche Foundation for Anemia Research, Weill Cornell Medical College
